Earnings Releases·Nov 12, 2026, 4:40 PM ET

DiaMedica Therapeutics — Third Quarter 2026 Earnings Summary

Cash, cash equivalents, and short-term investments declined to $34.9 million as of September 30, 2026, from $59.9 million at year-end 2025, with net cash used in operating activities rising to $26.0 million for the nine months ended September 30, 2026, compared to $21.3 million in the prior period.
Net loss increased to $31.5 million for the nine months ended September 30, 2026, from $24.0 million in 2025, driven primarily by a rise in R&D expenses to $25.4 million (up from $17.9 million), while G&A expenses decreased slightly to $7.2 million.
The company's current cash position is projected to fund clinical studies and operations through the fourth quarter of 2027, with the ReMEDy2 Phase 2/3 trial surpassing its 200-participant threshold for interim analysis expected in Q1 2027.
Regulatory progress includes Health Canada and EMA authorization for the global Phase 2 early-onset preeclampsia study, while the company addresses FDA feedback on nonclinical reproductive toxicity data required for an IND application for DM199.
Enrollment for the Phase 2 early-onset fetal growth restriction trial is complete in the first two cohorts, with preliminary results scheduled for presentation at a KOL event on November 24, 2026.